Podcast: 2-Drug ART
Key Decisions in HIV Care: Switching to a 2-Drug Single-Tablet Regimen

Released: November 10, 2021

Expiration: November 09, 2022

William R. Short
William R. Short, MD, MPH, FIDSA

Activity

Progress
1
Course Completed

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.

Listen as he gives his perspectives on:

  • Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TC
  • The SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patients
  • Real-world experience with switching to DTG/RPV from the OPERA study
  • The TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimen
  • The SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimen